Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -41.41% | 135.46% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.41% | 135.46% | |||
| Cost of Revenue | 1.84% | -1.24% | |||
| Gross Profit | -46.89% | 185.46% | |||
| SG&A Expenses | -0.53% | -7.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.63% | -2.17% | |||
| Operating Income | -154.43% | 193.05% | |||
| Income Before Tax | -191.34% | 154.97% | |||
| Income Tax Expenses | -93.88% | 64.63% | |||
| Earnings from Continuing Operations | -193.31% | 153.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -193.31% | 153.53% | |||
| EBIT | -154.43% | 193.05% | |||
| EBITDA | -145.30% | 204.87% | |||
| EPS Basic | -193.02% | 153.29% | |||
| Normalized Basic EPS | -182.36% | 160.54% | |||
| EPS Diluted | -195.29% | 152.02% | |||
| Normalized Diluted EPS | -186.38% | 157.71% | |||
| Average Basic Shares Outstanding | 0.31% | 0.45% | |||
| Average Diluted Shares Outstanding | -4.36% | 5.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||